Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NOX.AU
- Price
- 0.10
- Stock movement up
- +- (0.00%)
- Company name
- Noxopharm Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 28.93M
- Ent value
- 31.27M
- Price/Sales
- 5.54
- Price/Book
- 41.93
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 52.88%
- 1 year return
- -1.00%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-11
DIVIDENDS
NOX.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.54 |
| Price to Book | 41.93 |
| EV to Sales | 5.99 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 292.24M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.55M |
| Net receivables | 2.95M |
| Total current assets | 4.58M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 4.58M |
| Accounts payable | 450.87K |
| Short/Current long term debt | 2.48M |
| Total current liabilities | 3.87M |
| Total liabilities | 3.89M |
| Shareholder's equity | 689.96K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.10 |
| Daily high | 0.10 |
| Daily low | 0.10 |
| Daily Volume | 0K |
| All-time high | 1.58 |
| 1y analyst estimate | 1.00 |
| Beta | -0.31 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 23 Feb 2026 |
Downside potential
Loading...
Downside potential data
| NOX.AU | S&P500 | |
| Current price drop from All-time high | -93.73% | - |
| Highest price drop | -97.22% | -19.00% |
| Date of highest drop | 11 Jul 2025 | 8 Apr 2025 |
| Avg drop from high | -94.31% | -2.65% |
| Avg time to new high | - | 6 days |
| Max time to new high | 299 days | 89 days |
COMPANY DETAILS
Marketcap
28.93M
Marketcap category
Small-cap
Description
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found